BlackRock, Inc. 13D and 13G filings for Arrowhead Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-23 4:14 pm Purchase | 2023-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | BlackRock Inc. BLK | 13,303,281 12.400% | 592,650 (+4.66%) | Filing |
| 2023-01-26 08:52 am Unchanged | 2022-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | BlackRock Inc. BLK | 12,710,631 12.000% | 0 (Unchanged) | Filing |
| 2023-01-20 09:43 am Purchase | 2022-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | BlackRock Inc. BLK | 12,710,631 12.000% | 702,568 (+5.85%) | Filing |
| 2022-01-27 11:00 am Unchanged | 2021-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | BlackRock Inc. BLK | 12,008,063 11.500% | 0 (Unchanged) | Filing |
| 2022-01-25 3:03 pm Sale | 2021-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | BlackRock Inc. BLK | 12,008,063 11.500% | -555,069 (-4.42%) | Filing |
| 2021-01-26 6:52 pm Purchase | 2020-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | BlackRock Inc. BLK | 12,563,132 12.200% | 202,174 (+1.64%) | Filing |